Sandrock’s new Voyage

Al Sandrock may not have completed his neurology-focused mission at Biogen, but he’s pushing toward similar goals at the helm of Voyager, with a focus on novel CNS-penetrant gene therapy capsids that he hopes will be the lynchpin for the company’s revival.

Two years ago, Voyager Therapeutics Inc. (NASDAQ:VYGR) was in a difficult position. Three partnership deals had imploded, leading to the resignation of the CEO and CMO in May 2021. The refocus on Huntington disease gene therapy VY-HTT01 also failed to pan out, with preclinical toxicity leading to the program’s discontinuation. ...